High-Tech Gründerfonds leads €9m series-A for Audiocure

As part of the deal, hearing implant producer Med-El received exclusive licensing rights as well as a stake in the business, while existing investor HTGF increased its stake.

According to a statement, the company is planning to use the capital injection to start clinical trials on its flagship product, which addresses auditory disorders.

Previous funding
In May 2012, HTGF led a seed funding round for the business.

Company
Founded in 2010 and headquartered in Berlin, Audiocure develops therapeutic treatments for auditory disorders, including acute hearing loss and tinnitus. The company focuses its researches on a small molecule called AC102, which is yet to reach its first clinical trials phase.

People
High-Tech Gründerfonds – Martin Pfister (senior investment manager).
Audiocure Pharma – Hans Rommelspacher (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Venture
• Germany
• High-Tech Gründerfonds